Access to Cannabis for Medical Purposes Regulations

Crucial Innovations Corp. (OTC: CINV), Announces Completion of Reverse Merger with Eco Equity, Medical Cannabis operator in Zimbabwe, Africa

Retrieved on: 
Wednesday, October 26, 2022
CINV, SEC, Glass, SEC filing, Securities Exchange Act of 1934, Acquisition, ECO, Medical cannabis, Securities Act of 1933, Safe harbor, The O.C., Guernsey, OTC, Nature, Research, GLOBE, USD, Investment, Cannabis, Genetics, Access to Cannabis for Medical Purposes Regulations, Security (finance), Drug, Cannabinoid

The completion of the reverse takeover of CINV by Eco Equity Zimbabwe means Eco Equity Pty Limited Zimbabwe is now a wholly owned subsidiary of the publicly traded company CINV.

Key Points: 
  • The completion of the reverse takeover of CINV by Eco Equity Zimbabwe means Eco Equity Pty Limited Zimbabwe is now a wholly owned subsidiary of the publicly traded company CINV.
  • This is an important milestone in the evolution of Eco Equity and the increasingly global cannabis industry, said JP Doran, JPDs co-founder and chief executive.
  • "The reverse merger gives us the opportunity to accelerate our growth trajectory and will enable us to cement our position as one of the most progressive Cannabis companies globally.
  • This material contains statements about expected future events and/or financial results that are forward-looking in nature and as such are by definition subject to risks and uncertainties

Allied Corp Commends Colombian Government for Announcing the Final Approval of the Regulations for the Export of Cannabis From Colombia

Retrieved on: 
Monday, April 4, 2022
Company, Regulation, Federal government of the United States, Access to Cannabis for Medical Purposes Regulations, IP, Sumathi Best Television Current Reporting Award, Risk, Theft, Patient, Public expenditure, Allied Corporation, PTSD, THC, Risk factor, Perception, Research, Cannabinoid, CEO, Conversation, Comment, Electricity, Safety, Intention, Goal, Federation, Time, GLOBE, Consultant, Anxiety, Development, Cannabis, Depression, Terminology, Alliance, Insurance, Water, History, Research and development, Drug, Risk management, CBD

("Allied" or the Company) (OTCQB: ALID) is pleased to commend the Colombian Government for the final approval of Regulation 227 (the "Regulation") which describes the technical guidelines regarding the export of cannabis flower from Colombia.

Key Points: 
  • ("Allied" or the Company) (OTCQB: ALID) is pleased to commend the Colombian Government for the final approval of Regulation 227 (the "Regulation") which describes the technical guidelines regarding the export of cannabis flower from Colombia.
  • In October 2021, Allied was asked to provide first comment on the Regulation and then in November 2021, second comment.
  • On February 20, 2022, Regulation 227 was officially announced by the President of Colombia introducing the practical regulations and implementation plan for the export of cannabis flower.
  • On April 01, 2022, the Colombian Government has released final approval of the technical guidelines necessary for the export of cannabis flower.

Allied Corp Commends the Colombian Government for Passing Regulations that Advance the Export of Dried Cannabis Flower From Colombia

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Development, Depression, PTSD, Insurance, Electricity, Federation, Perception, Risk, Water, Public expenditure, Cannabis, Theft, Regulation, Hand, Allied Corporation, Research, Company, Safety, Conversation, Risk factor, Consultant, Terminology, Comment, Intention, Anxiety, IP, Federal government of the United States, Patient, Alliance, Cannabinoid, Sumathi Best Television Current Reporting Award, Access to Cannabis for Medical Purposes Regulations, Goal, History, CEO, Contract, Research and development, Time, Drug, Risk management, CBD

("Allied" or the Company) (OTCQB: ALID) is pleased to commend the Colombian Government for passing Regulation 227 (the "Regulation") on February 20, 2022, which aims to enable the export of cannabis flower from Colombia.

Key Points: 
  • ("Allied" or the Company) (OTCQB: ALID) is pleased to commend the Colombian Government for passing Regulation 227 (the "Regulation") on February 20, 2022, which aims to enable the export of cannabis flower from Colombia.
  • On July 23, 2021 the President of Colombia, President Ivan Duque, signed Decree 811 lifting the prohibition on exportation of dried cannabis flower from Colombia.
  • This, among other important advances, will enable Allied to begin exporting dried cannabis flower internationally.
  • Dried cannabis flower is the fastest growing product segment of the multi-billion dollar global cannabis industry (Source: Fortune Business Insights ).

Flora Growth Reports H1 2021 Financial Results and Provides Guidance for H2 Revenue Anticipated Between US$9-11M

Retrieved on: 
Thursday, August 19, 2021
Textiles, Manufacturing, Alternative Medicine, Food, Beverage, Health, Cosmetics, Retail, Agriculture, Natural Resources, Union, Industry, Company, Webcast, Ernst Loosen, Nasdaq, Koch, Access to Cannabis for Medical Purposes Regulations, Growth, Kalaya, City, Traction, Science, Tobacco, FLGC, SEC, Letter, European Union, TROPI, Central, CPG, Cosmetics, Heimat, Colombians, Â, Marketing, Awareness, IPO, NASDAQ, OTC, Food, Cannabis, Partnership, CEO, Sale, Ã, Intention, Exercise, Drug, Security (finance), Fine chemical, Management, Animal

Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).

Key Points: 
  • Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).
  • Flora Growth generated revenues of +$2M with a gross profit of 60% (unaudited), as compared to revenues of ~$100K for 2020.
  • Flora Growth is a foreign private issuer and is required to submit financial results on a half-year basis, with a 6-month window to file the unaudited results.
  • Following the presentation, Flora will offer analysts, media, and investors the opportunity to ask questions in a question-and-answer session.

Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

Retrieved on: 
Friday, August 13, 2021
Health Canada, Corona Labs Inc., THE, CSE, CORE, Intellectual property, Act, EST, Anxiety, Removal of cannabis from Schedule I of the Controlled Substances Act, Company, CDSA, Person, Patent, OTC, Blue jay, Drug prohibition law, GLOBE, Compliance, Research, Mouth, Biotechnology, Patient, Substance-related disorder, LABS, Technology, Psilocybin, WKN, Cancer, Depression, Adoption, Addiction, Access to Cannabis for Medical Purposes Regulations, R, Database, Pharmaceutical industry

They have also led educators in cannabinoid therapy and have worked with thousands of patients, doctors and cultivators.

Key Points: 
  • They have also led educators in cannabinoid therapy and have worked with thousands of patients, doctors and cultivators.
  • With a growing roster of clinics under our umbrella, Core One continues to execute on its long-term goal of developing an internal patient base for its biosythensized psilocybin and psychedelic treatments.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.
  • ON BEHALF OF THE BOARD OF DIRECTORS OF CORE ONE LABS INC.

James E. Wagner Cease Trade Order Issued - Failure to File Interim Financial Statements

Retrieved on: 
Thursday, July 30, 2020
Cannabis, Access to Cannabis for Medical Purposes Regulations, Pharmaceuticals policy, OTC Markets Group, Forward-looking statement, Legality of cannabis, Drug policy, Health

KITCHENER, ON, July 30, 2020 /CNW/ - James E. Wagner Cultivation Corporation (the "Corporation") (NEX: JWCA.H; OTCQX: JWCAF) announces a cease trade order was issued by the Ontario Securities Commission on July 29, 2020 for failure to file its interim financial statements for the three months ended March 31, 2020, including the related management discussion and analysis and interim filing certifications.

Key Points: 
  • KITCHENER, ON, July 30, 2020 /CNW/ - James E. Wagner Cultivation Corporation (the "Corporation") (NEX: JWCA.H; OTCQX: JWCAF) announces a cease trade order was issued by the Ontario Securities Commission on July 29, 2020 for failure to file its interim financial statements for the three months ended March 31, 2020, including the related management discussion and analysis and interim filing certifications.
  • The closing of the Transaction is currently set to occur on or before August 31, 2020, provided that all remaining conditions are satisfied.
  • James E. Wagner Cultivation Corporation's wholly owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly theAccess to Cannabis for Medical Purposes Regulations("ACMPR").
  • Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those implied in the forward-looking statements.

James E. Wagner Announces Court Approval of Sale of Assets

Retrieved on: 
Tuesday, June 2, 2020
Cannabis, Health, Access to Cannabis for Medical Purposes Regulations, Pharmaceuticals policy, Medicine, Legality of cannabis

The closing of the Transaction is currently set to occur on or before June 30, 2020, provided that all remaining conditions are satisfied.

Key Points: 
  • The closing of the Transaction is currently set to occur on or before June 30, 2020, provided that all remaining conditions are satisfied.
  • Readers are urged to consult the full text of all documents available on SEDAR and the Monitor's website for further, more detailed, information.
  • James E. Wagner Cultivation Corporation's wholly owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly theAccess to Cannabis for Medical Purposes Regulations("ACMPR").
  • JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis using an advanced and proprietary aeroponic platform named GrowthSTORM.

James E. Wagner Announces Director Resignation

Retrieved on: 
Monday, June 1, 2020
Cannabis, Health, Medicine, Access to Cannabis for Medical Purposes Regulations, Pharmaceuticals policy, Legality of cannabis

The Corporation wishes to express its gratitude to Mr. Woodworth for his service on the Board.

Key Points: 
  • The Corporation wishes to express its gratitude to Mr. Woodworth for his service on the Board.
  • The Corporation intends to appear before the Ontario Superior Court of Justice (Commercial List) on June 2, 2020 to seek an order approving the Trichome Financial bid.
  • James E. Wagner Cultivation Corporation's wholly owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly theAccess to Cannabis for Medical Purposes Regulations("ACMPR").
  • JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis using an advanced and proprietary aeroponic platform named GrowthSTORM.

James E. Wagner announces conclusion of Sales and Investor Solicitation Process with Trichome Financial Corp. as the "Successful Bidder"

Retrieved on: 
Tuesday, May 19, 2020
Access to Cannabis for Medical Purposes Regulations, Pharmaceuticals policy, Purchasing, Health, Articles

Trichome Financial was to be the "stalking horse" bidder in the SISP and the transaction contemplated by the Asset Purchase Agreement was to be the "stalking horse" bid (the "Bid").

Key Points: 
  • Trichome Financial was to be the "stalking horse" bidder in the SISP and the transaction contemplated by the Asset Purchase Agreement was to be the "stalking horse" bid (the "Bid").
  • Following the bid deadline in the SISP, Trichome Financial was declared the "Successful Bidder".
  • The JWC Group now intends to appear before the Court as soon as possible to seek an order approving the Bid.
  • James E. Wagner Cultivation Corporation's wholly owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly theAccess to Cannabis for Medical Purposes Regulations ("ACMPR").

Cannara Biotech Inc. appoints Mary Durocher as New Board Director

Retrieved on: 
Friday, May 15, 2020
Entheogens, Euphoriants, Medicinal plants, Rosids, Psychoactive drugs, Access to Cannabis for Medical Purposes Regulations, Pharmaceuticals policy, Cannabis, Marijuana

"Mary is broadly recognized across Canada as a leading regulatory and compliance authority in the Cannabis sector, and we are delighted that she is bringing her energy and integrity to Cannara," said Zohar Krivorot, President and CEO of Cannara.

Key Points: 
  • "Mary is broadly recognized across Canada as a leading regulatory and compliance authority in the Cannabis sector, and we are delighted that she is bringing her energy and integrity to Cannara," said Zohar Krivorot, President and CEO of Cannara.
  • "Her knowledge and insights regarding the industry will be important as we accelerate our cultivation capabilities and quickly transition to commercial sales."
  • Mary has been involved in the Cannabis industry since the infancy of the Marihuana for Medical Purposes Regulations introduction.
  • Leveraging Quebec's low electricity costs, Cannara Biotech Inc.'s facility will produce premium-grade indoor cannabis and cannabis-derivative products for the Quebec and Canadian markets.